A Phase 3 interventional study of Comparator: simvastatin and niacin (+) laropiprant in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-03-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.
Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 4th largest by enrollment of the 49 interventional ones that give a count, is one of 10 that started in 2007, is one of 26 in phase 3, and was the 23rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 10 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,216 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 240 across the 49 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Hypercholesterolemia by Merck & Co., Inc: 1 open now, 3 under way, 3 of them phase 3. Of 26 finished, 16 (62%) have results posted.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2007, is one of 17 in phase 3, and was the 5th registered.
Merck & Co., Inc’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing simvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 1,216 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
Drug: niacin (+) laropiprant
Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
Drug: Comparator: simvastatin · Drug: Comparator: atorvastatin calcium
simvastatin (20mg to 40mg) for 12 weeks.
Also known as: Zocor®
One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
Also known as: MK0524A
atorvastatin calcium (20mg to 40mg) for 12 weeks.
Also known as: atorvastatin
Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12
Time frame: Baseline and 12 Weeks
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
Time frame: Baseline and 12 Weeks
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and 12 Weeks
First Patient In: 30-Jul-2007 Last Patient Last Visit: 10-Jul-2008 Investigators: 161 sites participated: Australia-5; Austria-4; Canada-11; Czech Republic-5; Denmark-4; France-10; Germany-24; Hungary-6; Israel-4; Italy-11; Netherlands-2; Norway-10; Poland-11; Russian Federation-7; South Africa-9; Spain-4; Sweden-17; United States-17
| Milestone | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| Started | 606 | 610 |
| Completed | 474 | 537 |
| Not completed | 132 | 73 |
| Withdrew: Adverse event | 90 | 45 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol violation | 10 | 9 |
| Withdrew: Withdrawal by subject | 32 | 17 |
| Percent | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 | -10.0 (-12.6 to -7.4) | -5.5 (-7.4 to -3.5) |
| Percent | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12 | 15.8 (13.8 to 17.8) | 0.2 (-1.1 to 1.4) |
| Percent | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | -17.6 (-21.0 to -14.2) | -4.0 (-7.2 to -0.9) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ER Niacin/Laropiprant + Run-in Statin | — | — | — |
| Run-in Statin Dose Doubled | — | — | — |
| Event | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/602 | 0/609 |
| Acute myocardial infarctionCardiac disorders | 1/602 | 0/609 |
| Cardiac failure congestiveCardiac disorders | 1/602 | 0/609 |
| Eye dischargeEye disorders | 1/602 | 0/609 |
| Non-cardiac chest painGeneral disorders | 1/602 | 0/609 |
| Drug hypersensitivityImmune system disorders | 1/602 | 0/609 |
| Acute sinusitisInfections and infestations | 1/602 | 0/609 |
| Oral herpesImmune system disorders | 1/602 | 0/609 |
| Wound sepsisInfections and infestations | 1/602 | 0/609 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/602 | 0/609 |
| Event | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled |
|---|---|---|
| FlushingVascular disorders | 68/602 | 9/609 |
| PruritusSkin and subcutaneous tissue disorders | 52/602 | 10/609 |
| NauseaGastrointestinal disorders | 20/602 | 9/609 |
| DiarrhoeaGastrointestinal disorders | 16/602 | 4/609 |
| NasopharyngitisInfections and infestations | 13/602 | 15/609 |
| Abdominal pain upperGastrointestinal disorders | 12/602 | 4/609 |
| ParaesthesiaNervous system disorders | 12/602 | 2/609 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/602 | 12/609 |
| BronchitisInfections and infestations | 11/602 | 5/609 |
| RashSkin and subcutaneous tissue disorders | 11/602 | 0/609 |
| Age, Continuous(years) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Mean | 60.4 ± 9.7 | 60.6 ± 9.8 | 60.5 ± 9.7 |
| Sex: Female, Male(Participants) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Female | 304 | 289 | 593 |
| Male | 302 | 321 | 623 |
| Coronary Heart Disease Risk Category by Goal(Participants) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Low Risk at Goal | 27 | 26 | 53 |
| Low Risk Not at Goal | 16 | 14 | 30 |
| Multiple Risk at Goal | 91 | 82 | 173 |
| Multiple Risk Not at Goal | 92 | 71 | 163 |
| High Risk at Goal | 143 | 155 | 298 |
| High Risk Not at Goal | 237 | 262 | 499 |
| Lipid Modification Type/Dose at Run-in(participants) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Simvastatin 10 mg | 218 | 233 | 451 |
| Simvastatin 20 mg | 259 | 268 | 527 |
| Atorvastatin 10 mg | 129 | 109 | 238 |
| Fasting Serum Glucose (FSG)(mg/dL) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Mean | 108.3 ± 27.2 | 108.7 ± 27.7 | 108.5 ± 27.4 |
| High-density lipoprotein cholesterol(mg/dL) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Mean | 54.89 ± 14.45 | 54.97 ± 13.91 | 54.93 ± 14.17 |
| Low-density lipoprotein cholesterol(mg/dL) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Mean | 117.55 ± 28.66 | 115.82 ± 28.37 | 116.68 ± 28.52 |
| Triglycerides (TG)(mg/dL) | ER Niacin/Laropiprant + Run-in Statin | Run-in Statin Dose Doubled | Total |
|---|---|---|---|
| Median | 136.00 (46.00 to 594.00) | 124.00 (42.00 to 852.00) | 130.00 (42.00 to 852.00) |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of Jul 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Simvastatin · Niacin · MK-0524 · Atorvastatin